171P Pharmacodynamic (PD) biomarker analysis from CheckMate (CM) 8KX: A multitumor study of a subcutaneous (SC) formulation of nivolumab (NIVO) monotherapy

Autor: Jackson, C.G.C.A. ¹, Perumal, D. ², Lugowska, I. ³, O’Donnell, A. ⁴, North, R.T. ⁵, Calvo Ferrandiz, P.A. ⁶, Latten-Jansen, L.M. ⁷, Sánchez, C.G. ⁸, Medina Rodríguez, L.M. ⁹, Santoro, A. ¹⁰, Li, L. ², Sidik, K. ², Tang, T. ², Deutsch, J.S. ¹¹, Taube, J. ¹², Horak, C. ², Ravimohan, S. ², Lonardi, S. ¹³

Publikováno v: In Immuno-Oncology and Technology December 2022 16 Supplement 1

Clinical and survival characteristics of patients with BRAF-mutated metastatic colorectal cancer (mCRC) who receive metastases surgery in a Spanish cohort

Autor: Javier Soto, Marianela Bringas, Natalia Gutiérrez Alonso, Andrés J. Muñoz Martín, Aitana Calvo Ferrándiz, Gabriela Torres Pérez-Solero, Laura Ortega, Rocío Martín Lozano, Roberto Jiménez Rodríguez, Irene Gonzalez Caraballo, Carlos López Jiménez, Ana Gutierrez Ortiz de la Tabla, David Salomon Juliao Caamaño, Marc Ariant Cañete Muñoz, Mónica Benavente de Lucas, María Palma Gómez, Manuel Alva Bianchi, Íñigo Martínez Delfrade, Miguel Martin, Pilar Garcia-Alfonso

Publikováno v: Journal of Clinical Oncology. 41:66-66

66 Background: Patients with mCRC harboring BRAF mutation have worse prognosis and poor outcomes. However, those who have resectable metastatic disease and undergo surgery may have better outcomes compared to those who do not. Differences in clinical

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::732381776c306df4420b30647dabbbb2
https://doi.org/10.1200/jco.2023.41.4_suppl.66

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

Autor: Axel Grothey, Sara Lonardi, Victor Sandor, Neeltje Steeghs, Rona Yaeger, Elena Elez, Yong Sang Hong, Harpreet Wasan, Christina Guo, Jan H.M. Schellens, Tae Won Kim, Eric Van Cutsem, Ashwin Gollerkeri, Tormod Kyrre Guren, Fotios Loupakis, Line Schmidt Tarpgaard, Kati Maharry, Jayesh Desai, Lisa Anderson, Sergey Orlov, Aitana Calvo Ferrándiz, Jeroen Dekervel, Michael Braun, Per Pfeiffer, Asha Krishnan, Pilar García-Alfonso, Michael D Pickard, Scott Kopetz, Janna Christy-Bittel, Hendrik Tobias Arkenau, Takayuki Yoshino, Fortunato Ciardiello, Christopher Hunt Keir, Van Morris, Josep Tabernero

Publikováno v: Kopetz, S, Grothey, A, Yaeger, R, Van Cutsem, E, Desai, J, Yoshino, T, Wasan, H, Ciardiello, F, Loupakis, F, Hong, Y S, Steeghs, N, Guren, T K, Arkenau, H T, Garcia-Alfonso, P, Pfeiffer, P, Orlov, S, Lonardi, S, Elez, E, Kim, T W, Schellens, J H M, Guo, C, Krishnan, A, Dekervel, J, Morris, V, Ferrandiz, A C, Tarpgaard, L S, Braun, M, Gollerkeri, A, Keir, C, Maharry, K, Pickard, M, Christy-Bittel, J, Anderson, L, Sandor, V & Tabernero, J 2019, ' Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer ', New England Journal of Medicine, vol. 381, no. 17, pp. 1632-1643 . https://doi.org/10.1056/NEJMoa1908075

BACKGROUND: Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy. Inhibition of BRAF alone has limited activity because of path

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80ce4d5efea909032075f515edc5b20a
https://doi.org/10.1056/nejmoa1908075

Analysis of clinical characteristics and survival trends of BRAF mutated metastatic colorectal cancer (mCRC) patients receiving metastases surgery

Autor: Pilar Garcia-Alfonso, Natalia Gutiérrez Alonso, Marianela Bringas Beranek, Javier Soto Alsar, Carlos López Jiménez, Ana Gutierrez Ortiz de la Tabla, Roberto Jiménez Rodríguez, Rocío Martín Lozano, César Gutiérrez Pérez, Manuel Alva Bianchi, Andrés J. Muñoz Martín, Gabriela Torres Pérez-Solero, Laura Ortega, Aitana Calvo Ferrándiz, Juan Luis Catoya Villa, Marta Arregui Valles, Inmaculada Aparicio Salcedo, Miguel Martin

Publikováno v: Journal of Clinical Oncology. 40:e15552-e15552

e15552 Background: BRAF mutated mCRC patients have worse prognosis compared with BRAF wildtype mCRC. Within this group, those with resectable disease have a better prognosis compared to those with unresectable disease. However, it is not well known w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3cb5c3c9544c8385ff9e6f4ac79b502f
https://doi.org/10.1200/jco.2022.40.16_suppl.e15552

1654P Circulating tumor cells (CTCs) as prognostic factor for pancreatic cancer: Updated of a prospective study

Autor: Gutierrez Alonso, N. ¹, Benavente, M. ¹, Bringas Beranek, M. ², Soto Alsar, J. ², Palma, M. ¹, Cañete Muñoz, M.A. ¹, Lopez Alfonso, A. ³, Rahimi Mousavi, P. ⁴, Roche-Molina, M. ⁵, Del Monte-Millan, M. ², Megias, D. ⁶, García Pérez, Á. ⁷, Mullor Delgado, L.A. ⁷, Ortega Morán, L. ¹, Torres Perez-Solero, G. ¹, Morón, B.I. ⁸, Calvo Ferrandiz, P.A. ¹, García Alfonso, P. ¹, Martin Jimenez, M. ⁹, Munoz Martin, A.J. ¹

Publikováno v: In Annals of Oncology October 2023 34 Supplement 2:S912-S912